SBHMY (Sino Biopharmaceutical) FCF Margin % : 16.83% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sino Biopharmaceutical's Free Cash Flow for the six months ended in Jun. 2024 was $368 Mil. Sino Biopharmaceutical's Revenue for the six months ended in Jun. 2024 was $2,188 Mil. Therefore, Sino Biopharmaceutical's FCF Margin % for the quarter that ended in Jun. 2024 was 16.83%.

As of today, Sino Biopharmaceutical's current FCF Yield % is 7.59%.

The historical rank and industry rank for Sino Biopharmaceutical's FCF Margin % or its related term are showing as below:

SBHMY' s FCF Margin % Range Over the Past 10 Years
Min: 6.56 Med: 15.08 Max: 17.89
Current: 17.89

During the past 13 years, the highest FCF Margin % of Sino Biopharmaceutical was 17.89%. The lowest was 6.56%. And the median was 15.08%.

SBHMY's FCF Margin % is ranked better than
90.02% of 1012 companies
in the Biotechnology industry
Industry Median: -131.635 vs SBHMY: 17.89

Sino Biopharmaceutical FCF Margin % Historical Data

The historical data trend for Sino Biopharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical FCF Margin % Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

14.66

12.93

17.52

16.65

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															11.42	13.42	20.52	16.83	-

Competitive Comparison of Sino Biopharmaceutical's FCF Margin %

For the Biotechnology subindustry, Sino Biopharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Sino Biopharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sino Biopharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	610.911	/	3669.282
	=	16.65 %

Sino Biopharmaceutical's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	368.174	/	2188.154
	=	16.83 %

Sino Biopharmaceutical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.